- Tytuł:
- Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial
- Autorzy:
- Źródło:
- In The Lancet Oncology May 2019 20(5):649-662
Czasopismo naukowe